



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



CX-5461

Item No. 18392

CAS Registry No.: 1138549-36-6
Formal Name: 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-5H-benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide

MF: C₂₇H₂₇N₇O₂S

FW: 513.6


Purity: ≥98%

UV/Vis.: λ_{max}: 242, 292, 299, 339 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly



Laboratory Procedures

CX-5461 is supplied as a crystalline solid. A stock solution may be made by dissolving the CX-5461 in the solvent of choice. CX-5461 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of CX-5461 in these solvents is approximately 0.1, 1, and 2 mg/ml, respectively.

CX-5461 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CX-5461 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. CX-5461 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

CX-5461 is an inhibitor of ribosomal RNA (rRNA) synthesis. It selectively inhibits RNA polymerase I-driven transcription of rRNA in HCT116, A375, and MIA PaCa-2 tumor cells (IC₅₀s = 142, 113, and 54 nM, respectively) without affecting RNA polymerase II (IC₅₀ > 25 μM), DNA replication, or protein translation.^{1,2} At 50 mg/kg, CX-5461 demonstrates *in vivo* antitumor activity against human solid tumors in mouse xenograft models.¹

References

1. Drygin, D., Lin, A., Bliesath, J., *et al.* Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. *Cancer Res.* **71**(4), 1418-1430 (2011).
2. Haddach, M., Schwaebel, M.K., Michaux, J., *et al.* Discovery of CX-5461, the first direct and selective inhibitor of RNA polymerase I, for cancer therapeutics. *ACS Med. Chem. Lett.* **3**(7), 602-606 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/18/2016

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM